MedTrace Logo

Study of Acid Reflux in Asthma

NCT00069823 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 403

Last updated 2012-12-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if subjects with symptomatic asthma who are assigned to treatment with a proton pump inhibitor (PPI) drug such as Nexium have fewer asthma attacks than similar subjects assigned to placebo treatment.

Conditions

  • Asthma
  • Lung Diseases
  • Lung Diseases, Obstructive

Interventions

DRUG

Esomeprazole

Proton pump inhibitor 40 mg orally twice daily

DRUG

Placebo proton pump inhibitor

Placebo proton pump inhibitor

Sponsors & Collaborators

  • American Lung Association Asthma Clinical Research Centers

    collaborator OTHER

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Johns Hopkins Bloomberg School of Public Health

    lead OTHER

Principal Investigators

  • Robert Wise · Johns Hopkins University School of Public Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Primary Completion
2008-05-31
Completion
2008-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00069823 on ClinicalTrials.gov